Virpax Pharmaceuticals, a preclinical biotech developing new pain management drug technology, filed on Friday with the SEC to raise up to $18 million in an initial public offering.
Virpax Pharmaceuticals is developing innovative non-opioid and non-addictive pharmaceutical pain management
products using new drug delivery systems and technology. The company has exclusive global rights to develop, sell, and export a proprietary patented nonsteroid anti-inflammatory Topical Spray Film Delivery Technology for acute musculoskeletal pain and chronic osteoarthritis of the knee. Virpax also has exclusive rights to a patented injectable, long-acting “local anesthetic” Liposomal (Hydro) Gel Technology for postoperative pain management.
The West Chester, PA-based company was founded in 2016 and plans to list on the Nasdaq under the symbol VRPX. Virpax Pharmaceuticals filed confidentially on August 10, 2020. ThinkEquity is the sole bookrunner on the deal. No pricing terms were disclosed.
